The Food and Drug Administration today released for comment draft guidance clarifying what types of clinical and patient decision support software would no longer be regulated by the agency as a medical device under the 21st Century Cures Act. FDA Commissioner Scott Gottlieb, M.D., said the guidance generally excludes from regulation software that allows a health care provider or patient to independently review the basis for its treatment recommendations. In addition, FDA released draft guidance clarifying that certain digital health technologies, such as mobile apps intended solely to maintain or encourage a healthy lifestyle, generally fall outside the scope of FDA regulation under the Act, and final guidance adopting international principles for harmonizing the regulation of software with a medical purpose.

Related News Articles

Headline
The AHA today submitted a letter to the Office of Science and Technology Policy in response to its request for information on regulatory reform for artificial…
Chairperson's File
Public
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…
Headline
A blog published Oct. 21 breaks down the pressures driving physicians toward employment, including financial strain and administrative burden. The blog, co-…
Headline
Comments are due Oct. 27 to the Office of Science and Technology Policy on federal regulations that hinder artificial intelligence development, deployment or…
Headline
An AHA blog published today shares how HCA Healthcare in Nashville, Tenn., has been leveraging artificial intelligence to reduce risk and improve health…